The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
- 22 March 2007
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 559 (2-3), 132-137
- https://doi.org/10.1016/j.ejphar.2006.11.075
Abstract
We developed a reproducible, simple, and small-scale method for determining the re-uptake and release of monoamines (dopamine, serotonin (5-HT) and norepinephrine) using rat brain synaptosomes. These assays were then applied to study the effects of different kinds of non-medically used psychoactive drugs on monoamine re-uptake and release. The phenethylamine derivatives, 4-fluoroamphetamine, 2-methylamino-3,4-methylene-dioxy-propiophenone (methylone), 1-(1,3-benzodioxol-5-yl)-2-butanamine (BDB), and N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), had strong inhibitory effects on the re-uptake of dopamine, 5-HT and norepinephrine. 4-Fluoroamphetamine, methylone and BDB also strongly increased the release of the three monoamines, but MBDB increased 5-HT and norepinephrine release, but had little effect on dopamine release. However, 2,5-dimethoxy-4-iodophenethylamine (2C-I), 2,5-dimethoxy-4-ethylphenethylamine (2C-E), 2,5-dimethoxy-4-chlorophenethylamine (2C-C), 2,4,5-trimethoxyamphetamine (TMA-2) and 2,4,6-trimethoxyamphetamine (TMA-6), which are methoxylated phenethylamine derivatives, slightly influenced the re-uptake and release of monoamines. α-Metyltryptamine (AMT), a tryptamine derivative, was one of the strongest re-uptake inhibitors and releasers of the three monoamines. The tryptamine derivative, 5-methoxy-α-methyltryptamine (5-MeO-AMT), also strongly inhibited re-uptake and increased the release of the three monoamines. N,N-dipropyltryptamine (DPT), 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), 5-methoxy-N,N-methylisopropyltryptamine (5-MeO-MIPT), and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) inhibited monoamine re-uptake, but had a few effects on monoamine release. 1-(3-Chlorophenyl)piperazine (3CPP) and 1-(methoxyphenyl)piperazine (4MPP), which are piperazine derivatives, inhibited monoamine re-uptake and accelerated their release. The results suggest that some designer drugs strongly act on the central nerve system to the same extent as restricted drugs.Keywords
This publication has 13 references indexed in Scilit:
- Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and ratsPharmacology Biochemistry and Behavior, 2006
- N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’)Neuropsychopharmacology, 2004
- Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat BrainAnnals of the New York Academy of Sciences, 2004
- The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)Pharmacological Reviews, 2003
- (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine TransportersJournal of Pharmacology and Experimental Therapeutics, 2003
- Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brainEuropean Journal of Pharmacology, 2002
- Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine NeurotoxicityAnnals of the New York Academy of Sciences, 2000
- Triadimefon and Triadimenol: Effects on Monoamine Uptake and ReleaseToxicology and Applied Pharmacology, 1996
- Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the ratPsychopharmacology, 1991
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: EntactogensJournal of Psychoactive Drugs, 1986